VIDEO: Past, present and future of HER2-targeted therapies for breast cancer
In this video, Stan Lipkowitz, MD, PhD, chief of the women's malignancies branch in the National Cancer Institute's Center for Cancer Research, discusses a session on HER2-targeted therapies for breast cancer at AACR-NCI-EORTC.
Lipkowitz notes that at one time HER-positive breast cancer was considered one of the worst forms but is now highly treatable.
On the topic of HER2-targeted therapies, Lipkowitz said: "We now have two antibody drug conjugates, which leads to the question of what other antibody drug conjugates might be useful in that setting?"
Collapse
Prat A et al. HER2 heterogeneity implications for biology, tumor evolution, and treatment; Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10, 2021.
Krop IE et al. Novel treatment approaches for HER2-positive breast cancer; Presented at: 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (virtual meeting); Oct. 7-10, 2021.